Extracorporeal life support provision in COVID-19 patients - An international EuroELSO 2022 update survey
Abstrakt
Introduction: An analysis on the ECLS use for patients with respiratory or cardiac support in COVID-19 based on an international response to EuroELSO survey, aims to generate a more comprehensive understanding of ECLS role during the recent viral pandemic. Methods: EuroELSO announced the survey at the 10th annual congress in London, May 2022.
The survey covered 26 multiple-choice questions. Results: The survey returned 69 questionnaires from 62 centers across 22 European countries and seven centers across five non-European countries.
Most of the centers providing ECLS for COVID-19 patients had more than 30 runs for respiratory support since December 2019. In the same period, at least 31 runs in adult COVID-19 patients have been performed in 48 of 69 centers (69.6%).
The reported pediatric data from 18 centers is limited to less than the patients per center. Conclusion: Majority of the COVID-19 patients received respiratory ECLS support and adult patients dominated.
The indications and contraindications are broadly aligned with available guidelines. Most of the centers considered age >65 or biological age as a relative or absolute contraindication for ECLS in COVID-19.
ECLS withdrawal criteria in COVID-19 are controversial because the long-term outcomes after ECLS in COVID-19 and the impact of critical illness and the impact of long-COVID are still not known.